| Bioactivity | Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research[1][2]. |
| In Vivo | Stamulumab (MYO-029; 腹腔给药; 1-10 mg/kg/周; 持续 12 周) 在 SCID 小鼠体内以浓度依赖性方式增加骨骼肌质量。Stamulumab 导致肌纤维肥大而不是增生[1]。Stamulumab (静脉注射; 1, 5, 20, 100 mg/kg/周; 持续 4 周) 在 C57/SCID 小鼠中的中心清除率 (CL) 为 0.25 mL/h/kg[1].Pharmacokinetic Parameters of Stamulumab (MYO-029)[1]. |
| Name | Stamulumab |
| CAS | 705287-60-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. P Singh, et al. Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy. Clin Transl Sci. 2016 Dec;9(6):302-310. [2]. Kathryn R Wagner, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008 May;63(5):561-71. |